Pharmacological reduction of glucose availability with 2-deoxyglucose (2DG) suppresses pulsatile luteinizing hormone (LH) secretion in rats and growth-retarded lambs. Gonadal steroids enhance the glucoprivic suppression of LH secretion in rats. The present study determined if corticotropinreleasing hormone (CRH) plays a role in mediating oestrogen-dependent and -independent glucoprivic suppression of LH secretion. The study was conducted in ovariectomized (OVX) rats some of which received Silastic implants containing oestradiol-17b (OE 2 ) dissolved in peanut oil at 20 mg/ml to produce a physiological plasma level of OE 2 (30 pg/ml). Seven days after ovariectomy, the rats were stereotaxically implanted with a guide cannula into the third cerebral ventricle. Seven days later, blood samples were collected through an indwelling atrial cannula every 6 min for 3 h for LH pulse determination. After the first hour of blood sampling, a CRH antagonist, [d-Phe12, Nle21,38]hCRF-(21-41), or vehicle was injected into the third cerebral ventricle through the implanted cannula before 2DG administration through the indwelling atrial cannula. Pulsatile LH secretion was suppressed by 2DG (200 mg/kg b.w.) in the vehicle-treated rats bearing OE 2 implants. The CRH antagonist (5.65 nmol) blocked the suppressive effect of 2DG on pulsatile LH secretion in the OE 2 -treated OVX animals. On the other hand, in the absence of oestrogen, the effect of a twice greater dose of 2DG (400 mg/kg b.w.) was not blocked by five times greater amount of CRH antagonist (28.3 nmol). These results suggest the mechanisms mediating glucoprivic suppression of LH secretion involve two components: one is oestrogen-dependent and the other oestrogenindependent. CRH may be involved in the oestrogen-dependent component of glucoprivic suppression of LH secretion but not the oestrogen-independent one.
The reduction of glucose availability is considered as one of that noradrenergic input to the PVN suppresses LH secretion through a CRH-dependent pathway in the presence of oestrothe factors suppressing LH secretion under nutritional stress. Pharmacological reduction of glucose availability with gen or through a CRH-independent pathway in the absence of this steroid. This is because local noradrenaline injection 2-deoxyglucose (2DG) interrupts oestrous cyclicity in Syrian hamsters (1), and suppresses pulsatile luteinizing hormone into the PVN suppresses LH secretion through stimulating CRH release in oestradiol-17b (OE 2 )-primed ovariectomized (LH ) secretion in lambs (2) and rats (3) (4) (5) . Our previous study in female rats suggested that fasting activates the (OVX ) rats, but it causes a transient suppression that is not mediated by CRH in OVX animals (7). Accordingly, we catecholaminergic input from the solitary tract nucleus to the paraventricular nucleus (PVN ) to stimulate corticotropinpropose that fasting stress suppresses LH secretion in a CRHdependent/oestrogen-dependent manner and a CRHreleasing hormone (CRH ) release and then suppress gonadotropin-releasing hormone/LH secretion (6). It is thought independent/oestrogen-independent manner.
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Glucose availability is sensed by a glucose sensitive area in with CRH antagonist (5.65 nmol ) or vehicle into the third cerebral ventricle before 2DG administration at the dose of the lower brain stem, such as the area postrema and the information is sent to the PVN via the noradrenergic pathway.
200 mg/kg b.w. In the vehicle-treated animals, 2DG transiently suppressed pulsatile LH secretion. In contrast, pulsatile The existence of this pathway, which may be similar to that mediating fasting-induced suppression of LH secretion, is LH secretion was not blocked by 2DG treatment when the animals received an intracerebroventricular (i.c.v.) injection based on the following evidence: central administration of 2DG suppresses pulsatile LH secretion in rats (3) and lambs of the CRH antagonist. There was significant (P<0.05) difference in the percent change in mean plasma LH concen-(2); lesions of the area postrema, a circumventricular organ in the caudal brain stem, prevent the effect of 2DG on normal tration before and after 2DG treatment between the vehicleand CRH antagonist-injected groups (Mann-Whitney Uoestrous cyclicity in Syrian hamsters (8) ; glucoprivation stimulates noradrenaline release in the PVN; and the blockade test, Fig. 1 ). Figure 2 shows representative profiles of plasma LH levels of catecholamine synthesis in the PVN nullifies the glucoprivic suppression of LH secretion (5) . In addition, 2DG suppresses in the OVX individuals treated with 2DG (400 mg/kg b.w.) after i.c.v. injection of a CRH antagonist (28.3 nmol ) or LH secretion in the presence or absence of sex steroids in both genders, with steroid-treated animals being more sensitvehicle. Pulsatile LH secretion was suppressed by 2DG in both vehicle-injected and CRH antagonist-injected groups. ive to the glucoprivation (4). In this regard, glucoprivic suppression of LH secretion may be mediated by a CRHPretreatment of animals with the CRH antagonist at 28.3 nmol did not affect the 2DG-induced suppression of LH dependent and/or CRH-independent mechanism.
The present study was designed to determine whether CRH pulses. There was no significant difference in the percent change in mean plasma LH concentration between the groups mediates the oestrogen-dependent or oestrogen-independent 2DG effect on pulsatile LH secretion in female rats.
(Mann-Whitney U-test, Fig. 2 ). Figure 1 shows the representative profiles of plasma LH Our previous study revealed that oestrogen enhances the 2DG effect to inhibit pulsatile LH secretion, because 2DG levels in OE 2 -treated OVX individuals, which were injected suppresses LH secretion at 200 mg/kg b.w. in steroid-treated of evidence indicate that oestrogen is involved in activating CRH production or release in the PVN, since the primary rats, but not in females without steroid treatment (4). In the present study, therefore, the minimum doses of 2DG were transcript for CRH was increased by endotoxin lipopolysaccharide and c-fos mRNA was increased in CRH-immunochosen to induce suppression of LH secretion in both OVX and OE 2 -treated OVX animals according to the abovereactive cells on the morning of pro-oestrus in female rats (10). Both corticotropin release and corticosterone release in mentioned result. The CRH antagonist at the larger dose (28.3 nmol ) was ineffective in preventing the glucoprivic response to restraint stress were greater in pro-oestrus compared with other phases of oestrous cycle and these responses suppression of LH release in OVX animals. This dose of the antagonist in OVX rats was five times as much as that was were also higher in OE 2 -treated OVX rats than OVX rats (11) . Taken together, the increased sensitivity to 2DG in the used in OE 2 -primed OVX rats in the present study. It is reported that [-Phe12, Nle21,38]hCRF-(21-41) used in the presence of oestrogen might be due to the activation of CRH production or release by oestrogen. On the other hand, the present study is approximately 15 times more potent than that of a-helical CRF-(9-41) in terms of antagonizing cortico-2DG may not stimulate CRH to the level sufficient to suppress LH secretion in the absence of oestrogen and, tropin release (9). a-Helical CRF-(9-41) at 26 nmol i.c.v. injection into the third cerebral ventricle was effective in therefore, the higher amount of 2DG could suppress LH secretion through a pathway other than CRH release. preventing the suppression of LH release in rats that had fasted for 48 h (6). Therefore, the doses of 2DG and CRHAnother possibility is that opioidergic system mediating CRH action may be modulated by oestrogen, since the suppressive antagonist chosen in the present study are based on the previous experiments and seem to be within reasonable ranges effect of CRH on LH secretion is mediated through opioidergic system (12, 13) and naloxone-induced LH secretion is to evaluate their effect.
Discussion Results
In the present study, 2DG suppressed LH secretion in both dependent upon the presence of gonadal steroids in rats (14, 15) . OVX and OE 2 -treated OVX rats, but this effect was blocked by the CRH antagonist at a lower dose in OE 2 -treated OVX Arginine vasopressin (AVP) has been reported to mediate suppressive effects of stress on LH secretion (16) , and to play animals. This raises the possibility that reduced glucose availability suppresses LH secretion through stimulating a role in compensation for the CRH deficiency (17) . In addition, AVP and CRH synergistically stimulate cortico-CRH release in the presence of oestrogen, but through another pathway in the absence of oestrogen. Several lines tropin release from the isolated perfused anterior pituitary Statistical analysis cells (18) . In this context, AVP may have a co-operative LH pulses were identified by the PULSAR computer program (21) . The function with CRH or even an alternative function to CRH criteria for LH pulse detection have been previously described (22). Per cent in oestrogen-independent glucoprivic suppression of LH.
changes in mean plasma LH concentration before and after 2DG treatment
These results suggest the mechanisms mediating glucoprivic were determined by calculating the ratio of the difference in mean plasma suppression of LH secretion involve two components: one is LH concentrations between the pre-and post-2DG treatment periods to the mean LH concentration before 2DG treatment in individual animals.
oestrogen-dependent and the other oestrogen-independent. oestrogen-independent one.
